CClinicalTrials.gg
Sign In
RecruitingNCT05864794VULCANUpdated Jun 9, 2026

Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer

An interventional study of MRI in Non Small Cell Lung Cancer Metastatic, sponsored by University Medical Center Groningen. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Screening

From the registry’s dates

  • Started May 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.

02

Conditions studied

  • Non Small Cell Lung Cancer Metastatic

Browse trials for

Keywords

  • brain metastasis
  • screening
03

In context

Brain Neoplasms

1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.

This study's planned enrollment of 100 is above the median of 40 across 1,458 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
  • Fit for systemic treatment (PS 0-2) according to standard of care.
  • No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.

Exclusion criteria

Exclusion Criteria:

  • Prior/concomitant therapy for stage IV disease.
  • Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
  • Contraindications for MRI scan with contrast as per standard of care protocol of the institution.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Screening population

    Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease.

    Diagnostic Test: MRI

Interventions

  • Diagnostic testMRI

    MRI scan of the brain

06

What researchers measure

Primary outcomes

  1. Clinical value of the MRI

    Clinical value of the MRI evaluated by the treating thoracic oncologist and assessed by questionnaires completed on three timepoints.

    Time frame: up to 6 months after the MRI

07

Study locations

3 of 3 sites recruiting
  • University Medical Center Groningen
    Groningen, Provincie Groningen 9713LZ, Netherlands
    • Frederike Bensch, MD, PhD · Contact
    Recruiting
  • Maastricht UMC+
    Maastricht, Netherlands
    Recruiting
  • Ommelander Ziekenhuisgroep
    Scheemda, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864794
Lead sponsor
University Medical Center Groningen
Responsible party
Sponsor
First posted
May 18, 2023
Start date
May 13, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 9, 2026

Study contacts

F. Bensch, MD, PhD
Contact
f.bensch@umcg.nl
0031503616161
L.B.M. Hijmering, MD
Contact
l.b.m.hijmering-kappelle@umcg.nl
0031503616161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Brain Neoplasms→

Other studies from this sponsor

University Medical Center Groningen

Start the discussion